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Abstract
Impaired renal function is a risk factor for cardiovascular disease and an adverse prognostic
factor in patients with established cardiovascular disease. In addition, with current wide-
spread use of invasive procedures in the treatment of acute myocardial infarction, contrast-
-induced nephropathy is a growing problem in this patient population. In acute myocardial
infarction, impaired renal function may result from underlying kidney disease, acute renal
failure, and the effect of drugs and contrast agents used during diagnostic procedures or
treatment. These various causes may coexist, resulting in significantly worse outcomes. Prompt
recognition of the degree of renal function impairment and institution of appropriate preven-
tive and therapeutic measures are among major goals of in-hospital management of these
patients. A commonly used method to evaluate renal function is the determination of glomeru-
lar filtration rate. Appropriate nephroprotective treatment should be used in patients at risk of
contrast-induced nephropathy. The most commonly used methods include the use of iso-
-osmotic contrast agents and appropriate hydration in the periprocedural period. Studies
are currently under way to evaluate nephroprotective properties of other drugs such as
N-acetylcysteine, sodium chloride and sodium bicarbonate solutions, mannitol, and statins.
Results of some studies suggest that these measures may effectively reduce the number of renal
function deterioration events in patients with acute myocardial infarction.
Regardless of the cause, impaired renal function in acute myocardial infarction is a signifi-
cant adverse prognostic factor. Thus, despite some inconsistent views regarding the optimal
management strategy, intensive diagnostic, preventive, and therapeutic measures are clearly
necessary in patients with acute myocardial infarction and impaired renal function. (Cardiol J
2009; 16, 5: 400–406)
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Introduction
Percutaneous coronary diagnostic and thera-
peutic procedures require intravascular contrast
agent administration that is a major risk factor of
contrast-induced nephropathy (CIN) and acute re-
nal failure during the hospitalization.
In Europe, CIN is the third most common cause
of acute in-hospital renal failure, leading to prolonged
hospitalizations and increased treatment costs.
Impaired renal function (IRF) is a risk factor
for cardiovascular disease and an adverse prognos-
tic factor in patients with established cardiovascu-
lar disease [1]. Many clinical and population stud-
ies demonstrated that IRF is an independent prog-
nostic factor during short- and long-term follow-up
of patients with acute coronary syndromes (ACS),
including acute myocardial infarction (AMI) [2, 3].
In addition, renal dysfunction was shown to be an
adverse predictive factor in AMI regardless of the
reperfusion strategy used [2, 4–6].
Currently, percutaneous coronary intervention
(PCI) is the preferred treatment strategy also in pa-
tients with IRF, as it is associated with a higher rate
of effective reperfusion and lower mortality compared
to thrombolytic therapy [7]. In some patients, how-
ever, PCI carries a risk of CIN. Patients with under-
lying IRF [8] or IRF secondary to hemodynamic com-
promise in ACE are at particular risk of this compli-
cation. Other risk factors for CIN include large
amounts of contrast agent administered during PCI
and inability to use appropriate prevention. Thus,
identification of patients at risk and institution of ap-
propriate preventive measures are clearly justified.
A registry of patients with ACS in Poland was
established in 2003. The rates of various degrees
of IRF in patients with ACS are shown in Table 1.
Definitions
To address the issue of chronic kidney disease
(CKD), a group of experts working under the aus-
pices of National Kidney Foundation developed cli-
nical practice guidelines known as Kidney Disease
Outcomes Quality Initiative (K/DOQI) [9].
A consequence of CKD is decreased glomeru-
lar filtration rate (GFR) [10]. This renal function im-
pairment develops gradually but may be noted al-
ready in early stages of CKD, and GFR is the most
precise marker of renal function [11]. Thus, a new,
five-stage classification of CKD severity was pro-
posed in the K/DOQI guidelines based on the de-
gree of GFR reduction:
— stage I: GFR > 90 mL/min/1.73 m2 (a transient
increase in GFR may even be noted at this stage);
— stage II: GFR 60–89 mL/min/1.73 m2;
— stage III: GFR 30–59 mL/min/1.73 m2;
— stage IV: GFR 15–29 mL/min/1.73 m2;
— stage V: GFR < 15 mL/min/1.73 m2.
The latter stage is, in fact, chronic end-stage re-
nal failure that requires renal replacement therapy.
Normal GFR is approximately 130 ± 20 mL/
/min/1.73 m2 in men, 115 ± 15 mL/min/1.73 m2 in
women. Thus, CKD is not synonymous with chronic
renal failure, as the latter is the terminal stage of
CKD as defined in the classification introduced in
the K/DOQI guidelines.
Chronic kidney disease
American National Kidney Foundation defined
diagnostic criteria of CKD based on both GFR and
structural and functional renal kidney changes.
According to these criteria, CKD may be diagnosed
in two situations [9]:
— if impaired renal function as defined by redu-
ced GFR is sustained for more than three mon-
ths, and GFR is reduced to less than 60 mL/
/min/1.73 m2, CKD may be diagnosed regar-
dless of any other diagnostic criteria;
— if GFR is normal or exceeds 60 mL/min/1.73 m2
(stage I and II), CKD may be diagnosed if su-
stained structural and functional renal kidney
changes are seen for more than three months,
Table 1. Proportions of patients with acute coronary syndromes and various stages of chronic kidney
disease as defined based on impaired glomerular filtration rate. Source: PL–ACS Registry.
Glomerular filtration rate
30–59 mL/min/1.73 m2 15–29 mL/min/1.73 m2 < 15 mL/min/1.73 m2
(Stage III)  (Stage IV)  (Stage V)
UA 23% 1.5% 1%
NSTEMI 28% 3.9% 1.8%
STEMI 20% 2.4% 0.9%
UA — unstable angina; NSTEMI — non-ST segment elevation myocardial infarction; STEMI — ST segment elevation myocardial infarction
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based on abnormal results of additional blood
and/or urine testing or morphological abnorma-
lities in imaging studies.
According to this definition, the diagnosis of
stage I and II CKD requires additional features of
renal damage, while GFR reduced to less than
60 mL/min/1.73 m2 is sufficient to diagnose CKD
without the presence of any other diagnostic criteria.
In clinical practice, GFR is most commonly
calculated based on creatinine clearance or estimat-
ed (so called estimated glomerular filtration rate,
eGFR) using the Cockroft-Gault formula or the
Modification of Diet in Renal Disease (MDRD)
study formula. Recent data suggest the MDRD for-
mula is the most reliable and objective approach to
estimate GFR [12, 13]. The use of the MDRD for-
mula is recommended in the K/DOQI guidelines in
all patients except those on a vegetarian diet and
subjects with severely reduced body mass. In these
groups, renal function evaluation should be based
on the determination of creatinine clearance. Four
modifications of the MDRD formula have been de-
scribed, and the simplest of them is as follows:
eGFR [mL/min/1.73 m2] = 186.3 × (serum
creatinine)–1.154 × (age)–0.203 × C
where C is a constant equal to 1 in men, 0.762 in
women, and 1.21 in Afro-Americans. Online ver-
sions of eGFR calculators are widely available in the
Internet (see for example http://www.kidney.org/
/professionals/kdoqi/gfr_calculator.cfm).
Contrast-induced nephropathy
Contrast-induced nephropathy is defined as
acute impairment of renal function that occurs 24–
–48 hours after an intravenous contrast agent ad-
ministration and results in an increase in serum cre-
atinine level by at least 25% compared to the base-
line values, if no alternative explanation of renal
function impairment can be offered [14]. Creatinine
level peaks at approximately 2–3 days after the con-
trast agent administration and returns to the base-
line values by 14 days. Unfortunately, some patients
may develop acute renal failure requiring dialysis
therapy [15].
Pathophysiology
Impaired renal function has a negative effect
of atherosclerotic vascular lesions, leading to in-
creased production of atherogenic factors, proteinu-
ria, increased inflammatory activity (as manifested
by high fibrinogen and C-reactive protein levels),
increased level of oxidation products, impaired ni-
tric oxide production, and accelerated vascular cal-
cification [16–18]. All these effects contribute to
faster progression of atherosclerosis in patients
with IRF, involving both coronary and peripheral
vessels. In addition, resulting atherosclerotic
plaques are thickened and more calcified [11, 19].
Clinical aspects of renal failure in
acute myocardial infarction
Renal function should be promptly evaluated
in all patients admitted due to AMI. The major labo-
ratory parameter is serum creatinine level which
allows eGFR calculation. Values below 60 mL/min/
/1.73 m2 are associated with markedly worse prog-
nosis, because these patients are significantly more
likely to develop CIN [14]. Thus, management of
these patients should be modified accordingly and
this issue is discussed in more detail below. As high-
-lighted in the K/DOQI guidelines, risk assessment
should be based on eGFR evaluation using the
MDRD formula [9]. If serum creatinine level is not
available promptly, thorough history should be tak-
en regarding past renal function and/or kidney dis-
ease. This evaluation of renal function may be omit-
ted only if even short delay in the use of contrast
agent for diagnostic or therapeutic purposes would
pose more risk for the patient than any future com-
plications of the contrast agent administration [9].
Renal function may deteriorate after AMI. This
may result from both hemodynamic compromise
affecting glomerular perfusion and diagnostic and/or
therapeutic procedures requiring the use of a con-
trast agent. The degree of renal function impair-
ment resulting from these factors may vary from
mild reduction in GFR to the occurrence of acute
renal failure. The latter develops most frequently
in patients with AMI complicated by a cardiogenic
shock or with underlying renal function impairment.
Important prognostic factors include time to reper-
fusion, infarct location, and coexisting conditions,
particularly diabetes.
Renal function impairment or CIN may occur
in any patient with AMI or undergoing any diagnos-
tic and/or therapeutic procedures involving an in-
travenous contrast agent administration. However,
some subsets of patients require higher level of
diagnostic vigilance or even appropriate manage-
ment modifications.
The major predictive factor for CIN is GFR,
with the increase in risk being proportional to the
degree of IRF [15]. Thus, CKD is the major concomi-
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tant clinical condition contributing to the develo-
pment of CIN. The risk of CIN is also increased in
patients with diabetes, anemia or heart failure, pa-
tients above 75 years of age, and patients in cardio-
genic shock [14]. The occurrence of CIN is in turn
associated with higher risk of acute renal failure.
Impact of IRF on the prognosis
in AMI treated with PCI
The effect of IRF on the management and prog-
nosis in patients with AMI treated with PCI was
studied by many researchers. For example, the
group of Suchetry Vasu analyzed the effect of im-
paired renal function on in-hospital prognosis in
patients with AMI treated with PCI. The patients
were divided in two groups, with less severe (sta-
ge 0–III) or more severe (stage III–V) CKD. The
cutoff serum creatinine was 2.5 mg/dL. In this study,
patients with more severe CKD were much more
likely to suffer from coexisting conditions such as
diabetes, hypertension, and peripheral vascular dis-
ease. These patients were also at significantly high-
er risk of developing cardiogenic shock or cardiac
failure, with significantly increased in-hospital mor-
tality (23.4% vs. 4.2%, p < 0.001) [16]. Worse out-
comes in patients with more severe CKD may by
largely explained by more severe coronary artery
disease in this group, leading to less beneficial ef-
fects of PCI compared to patients without IRF [20].
However, more advanced CKD remained an inde-
pendent prognostic factor affecting in-hospital mor-
tality even after controlling for confounders [16]. An
analysis of HIJAMI registry demonstrated that long-
-term outcomes in patients with AMI treated with
PCI were similar to the results reported by Vasu
et al. [21]. This worse prognosis may be related to
specific biochemical and physiological features of
CKD, as periprocedural bleeding events and strokes
are much more likely in these patients. In addition,
CKD affects metabolism of drugs used in the treat-
ment of AMI, such as aspirin, beta-blockers, and
angiotensin-converting enzyme inhibitors. All these
factors result in a higher risk of complications and
worse outcomes [17]. As mentioned above, reduced
survival of patients with IRF was highlighted in the
HIJAMI registry analyses that showed that impaired
renal function is associated with a higher likelihood
of unsuccessful PCI [22]. Eijkelkamp et al. [23]
evaluated more than 6000 patients with AMI who
were followed for approximately 27 years. Average
yearly increase in serum creatinine level in patients
who suffered an AMI was 3.1% compared to 0.4%
in the control group of patient with no history of
AMI (p = 0.005). This resulted in a significantly
higher age-related fall in GFR (2.2 vs. 0.5 mL/min/
/1.73 m2 per year, p = 0.006) [23]. These results
may perhaps be explained by accelerated glomeru-
losclerosis in patients who suffered an AMI but the
exact determination of the pathomechanism and any
therapeutic possibilities in this regard awaits fur-
ther studies. Many observations suggest bidirec-
tional pathogenetic interactions between IRF and
AMI, as impaired renal function seems to increase
the risk of AMI, but the AMI itself is a risk factor
for IRF.
More transient renal function impairment also
seems to have an adverse prognostic effect in pa-
tients who suffered an AMI. In the PREVEND
study, Lathamsetty et al. [24] demonstrated that in-
hospital rise in creatinine level was associated with
significantly worse outcomes regardless of any fur-
ther improvement in renal function. In this popula-
tion, even a short-lasting rise in creatinine level
resulted in significantly increased mortality com-
pared to patient who did not experience renal func-
tion impairment (7.4% vs. 27%). In addition, this
increase in mortality was similar to patients in
whom creatinine level remained permanently ele-
vated (27% vs. 23%). A short-term rise in creati-
nine level was shown to be an independent predic-
tor of mortality at six months [24]. Again, mecha-
nisms of these worse outcomes remain to be
determined.
The degree of post-infarction GFR reduction
is largely related to the mechanism of renal dam-
age. Kowalczyk et al. [25] evaluated prognostic dif-
ferences between patients with IRF due to under-
lying CKD or induced by an administration of a con-
trast agent. The most important independent adverse
prognostic factor in this study was the occurrence
of cardiogenic shock. Although the least favorable
long-term outcomes were noted in patients with
CKD, controlling for confounders (including cardio-
genic shock) revealed that CIN was even stronger
adverse prognostic factor than CKD, particularly in
patients with diabetes. High mortality among pa-
tients with CKD in this study may be explained by
a higher rate of cardiogenic shock in this group.
Other common factors than cardiogenic shock
and CKD that increase the risk of CIN include dia-
betes, time to reperfusion exceeding six hours, and
the anterior wall infarct location [26]
Prevention and treatment
The current management of ST segment ele-
vation ACS is discussed in the regularly updated
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European Society of Cardiology (ESC) guidelines
and American guidelines. The latest 2008 ESC
guidelines on ST segment elevation ACS recom-
mend that patients with renal dysfuncion should be
treated in a similar way to the general population
of AMI patients, but renal disease should be taken
into account when choosing reperfusion strategy
and considering specific pharmacotherapy due to
worse outcomes in this patients group [27]. Both
European and American guidelines do not provide
separate recommendations for a growing population
of patients with CKD and chronic renal failure.
These guidelines are generally based on the results
of randomized clinical trials and registry studies
performed in wide populations of AMI patients. For
the purpose of the present review, we analyzed
studies on which the 2005 PCI guidelines were
based [28]. Inclusion criteria in these studies show
significant heterogeneity in terms of acceptable
renal function. In approximately half of the studies
on which level of evidence A or B recommendations
were based, the exclusion criteria included any re-
nal failure or elevated serum creatinine (> 1.7–
–3.5 mg/dL) [29]. In this regard, published recom-
mendations on the invasive treatment in AMI may
be considered of limited value in patients with AMI
and coexisting IRF. Studies are currently under way
to determine the optimal management strategy in
these patients. As mentioned above, even a tran-
sient rise in creatinine level is an adverse prognos-
tic factor in AMI [24]. This increase in risk is main-
ly related to the occurrence of CIN. The Canadian
Radiological Society published guidelines on pre-
vention of CIN in patients undergoing diagnostic
and therapeutic procedures requiring an intrave-
nous contrast agent administration and recommend-
ed, particularly in patients at high risk of CIN (i.e.,
with GFR < 30 mL/min), the use of iso-osmolar and
low-osmolar contrast agents which are less neph-
rotoxic compared to the high-osmolar contrast
media [15]. However, Aspelin et al. [30] demon-
strated advantage of an iso-osmolar over a low-os-
molar contrast agent in high-risk patients with dia-
betes. Due to large differences in osmolality be-
tween particular agents, further studies are
necessary to establish the optimal choice of a con-
trast agent. According to the Canadian Radiologi-
cal Society guidelines, the use of 100–140 mL of
a contrast agent per procedure is associated with
a minimal risk of CIN. These guidelines also recom-
mend routine hydration with 0.9% NaCl or NaHCO3
solution to increase volemia [15]. In patients under-
going acute coronary interventions, Masuda et al.
[31] demonstrated a lower rate of CIN with the
use of sodium bicarbonate compared to sodium chlo-
ride (7% vs. 35%, p = 0.01). A free radical scaven-
ger, N-acetylcysteine, has also been recommen-
ded, particularly in patients with GFR < 60 mL/min
[32]. Nallamothu et al. [33] performed a metaana-
lysis of 20 randomized studies evaluating the effect
of acetylcysteine on the incidence of CIN and
showed a non-significant trend toward a lower rate
of CIN in patients receiving acetylcysteine. In
a randomized REMEDIAL study in 326 medium-
and high risk patients undergoing coronary or pe-
ripheral angiography and/or angioplasty procedures,
Briguori et al. [34] demonstrated an advantage of
sodium bicarbonate and acetylcysteine combination
over both sodium chloride with acetylcysteine and
sodium chloride with acetylcysteine and ascorbic
acid in terms of reduction of the incidence of CIN
(1.9% vs. 9.9% vs. 10.3%). Recently, Kelly et al. [35]
published a metaanalysis of 41 randomized studies
including 3622 patients undergoing various diagnos-
tic and therapeutic procedures requiring the use of
a contrast agent and demonstrated an advantage of
N-acetylcysteine, mannitol and theophyllin over
periprocedural fluid administation only in terms of
the effectiveness of CIN prevention.
Large doses of statins were also reported to
have nephroprotective properties in AMI patients
treated with PCI, and this effect is probably associ-
ated with the antioxidant activity of these drugs
[36]. Patti et al. [37] prospectively studied more
than 4000 patients undergoing PCI and found
a lower rate of CIN among statin-treated patients
compared to controls (3% vs. 27%, p < 0.0001).
However, subgroup analysis showed no nephro-
protective effect of statins in patients with base-
line creatinine clearance < 40 mL/min. Similar
results in AMI patients treated with primary PCI
were reported by Zhao et al. [38] who noted a sig-
nificantly lower rate of CIN in patients who were
pre-treated with statins (7.1% vs. 20.6%, p < 0.01).
In contrast, a randomized, double-blind PROMISS
study showed no benefit of simvastatin (in a total
dose of 160 mg) in terms of reduction of the inci-
dence of CIN in patients with renal failure (creat-
inine clearance < 60 mL/min or serum creatinne
> 1.1 mg/dL) undergoing coronary angiography
(2.5% vs. 3.4%, p = 1.00) [39]. Nephroprotective
properties of many other treatments during inva-
sive cardiac procedures including those used in the
treatment of AMI were also evaluated, but no clear
and reliable evidence of their effectiveness exist
to date [40].
General recommendations of the Canadian
Radiological Society regarding prevention of CIN
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in patients undergoing procedures requiring an
intravenous contrast agent administration de-
pending on the baseline GFR are summarized in
Table 2 [15].
Summary
As highlighted in the present review, IRF has
a significant effect on the management and prog-
nosis in patients with AMI. Worse renal function is
associated with a significantly higher risk of com-
plications, including adverse cardiovascular events
and mortality, both in hospital and during long-term
follow-up. Review of the literature demonstrates
significant heterogeneity in the approach to the
evaluation of renal function and the definition of
IRF, resulting in discrepant data on the rate of var-
ious degrees of IRF in patients with ACS. In addi-
tion, many studies were performed in populations
with only milder degree of renal function impair-
ment, excluding patients with more advanced kid-
ney disease.
However, regardless of these methodological
issues and different definitions, renal dysfunction
is undoubtedly a major prognostic factor in AMI, and
it appears that efforts to diagnose, prevent and treat
this condition became a part of routine management
in this patient population.
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